# LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Source: https://onco.cc/trials/nct07391566/  
OnCo record `nct07391566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab (glioblastoma use) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Luye Pharma Group Ltd., not yet recruiting.

## Summary

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation is a phase 1/2, interventional study registered as NCT07391566 by Luye Pharma Group Ltd., with a registry enrolment figure of 99 participants, started 2026-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: LPM6690176; Bevacizumab; FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan). Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Phase Ib: Dose-limiting toxicities (DLTs); Phase Ib: Maximum tolerated dose (MTD); Phase 1b: Recommended Phase 2 Dose (RP2D). Colorectal eligibility wording from the registry: "Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07391566
- Phase: 1/2
- Setting: Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LPM6690176 Capsules in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
- Sponsor: Luye Pharma Group Ltd.
- Enrolled: 99

## Sources

- ClinicalTrials.gov NCT07391566: https://clinicaltrials.gov/study/NCT07391566

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)
- companies: [Luye Pharma Group](https://onco.cc/companies/luye-pharma/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07391566.json